Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “antagonist”

678 pharma patents match "antagonist" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 678
Index total 30,257
Page 10 / 29

Quick answer

This filtered view shows 678 pharmaceutical patents matching "antagonist" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

678 results for “antagonist” · 30,257 patents in full index Clear search

  1. US 10066017

    Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 4, 2018 · Expires Aug 30, 2038

    granted
  2. US 10059771

    Methods for treating nasal polyposis by administering an IL-4R antagonist

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 28, 2018 · Expires Aug 23, 2038

    granted
  3. US 10059744

    α4β7 thioether peptide dimer antagonists

    Protagonist Therapeutics, Inc. · Granted Aug 28, 2018 · Expires Aug 23, 2038

    granted
  4. US 10047122

    Peptide and peptide mimetic binding antagonists of polo-like kinase 1 polo box domain and methods of use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Aug 14, 2018 · Expires Aug 9, 2038

    granted
  5. US 10035833

    Vascular endothelial growth factor antagonists and methods of making

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jul 31, 2018 · Expires Jul 26, 2038

    granted
  6. US 10011647

    IL-33 antagonists and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 3, 2018 · Expires Jun 28, 2038

    granted
  7. US 10011588

    1,2-substituted cyclopentanes as orexin receptor antagonists

    Takeda Pharmaceutical Company Limited · Granted Jul 3, 2018 · Expires Jun 28, 2038

    granted
  8. US 10005771

    Bicyclic derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities

    Almirall, S.A. · Granted Jun 26, 2018 · Expires Jun 21, 2038

    granted
  9. US 10000456

    Polycyclic compounds as lysophosphatidic acid receptor antagonists

    AMIRA PHARMACEUTICALS, INC. · Granted Jun 19, 2018 · Expires Jun 14, 2038

    granted
  10. US 10000477

    Dopamine D3 receptor antagonist compounds

    Indivior UK Limited · Granted Jun 19, 2018 · Expires Jun 14, 2038

    granted
  11. US 9987253

    Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

    Jenrin Discovery, LLC · Granted Jun 5, 2018 · Expires May 31, 2038

    granted
  12. US 9980936

    BH4 antagonists and methods related thereto

    The Board of Regents of the University of Texas System · Granted May 29, 2018 · Expires May 24, 2038

    granted
  13. US 9975875

    Diamide compounds having muscarinic receptor antagonist and Beta2 adrenergic receptor agonist activity

    Theravance Respiratory Company, LLC · Granted May 22, 2018 · Expires May 17, 2038

    granted
  14. US 9974742

    Emulsion formulations of an NK-1 receptor antagonist and uses thereof

    Heron Therapeutics, Inc. · Granted May 22, 2018 · Expires May 17, 2038

    granted
  15. US 9951010

    Compounds as CRTH2 antagonist and uses thereof

    SUNSHINE LAKE PHARMA CO., LTD. · Granted Apr 24, 2018 · Expires Apr 19, 2038

    granted
  16. US 9951017

    S1P3 antagonists

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Apr 24, 2018 · Expires Apr 19, 2038

    granted
  17. US 9926272

    Biphenyl compounds useful as muscarinic receptor antagonists

    Theravance Biopharma R&D IP, LLC · Granted Mar 27, 2018 · Expires Mar 22, 2038

    granted
  18. US 9914763

    VEGF antagonist formulations suitable for intravitreal administration

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 13, 2018 · Expires Mar 8, 2038

    granted
  19. US 9896502

    Antagonist antibodies directed against calcitonin gene-related peptide and methods using same

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Feb 20, 2018 · Expires Feb 15, 2038

    granted
  20. US 9896509

    Use of antagonists of the interaction between HIV GP120 and α4β7 integrin

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Feb 20, 2018 · Expires Feb 15, 2038

    granted
  21. US 9890210

    Antagonist antibodies directed against calcitonin gene-related peptide

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Feb 13, 2018 · Expires Feb 8, 2038

    granted
  22. US 9890211

    Antagonist antibodies directed against calcitonin gene-related peptide

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Feb 13, 2018 · Expires Feb 8, 2038

    granted
  23. US 9884907

    Methods for treating headache using antagonist antibodies directed against calcitonin gene-related peptide

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Feb 6, 2018 · Expires Feb 1, 2038

    granted
  24. US 9884908

    Methods for treating headache using antagonist antibodies directed against calcitonin gene-related peptide

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Feb 6, 2018 · Expires Feb 1, 2038

    granted